

# LEO Pharma pipeline 2024

*Continuing to build on LEO Pharma's legacy and track record for innovation*

PROJECT	DESCRIPTION	INDICATIONS	PARTNERS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	FILING	REGIONS
<b>Calcipotriol</b> LP0053	Calcipotriene and betamethasone dipronate foam	Plaque Psoriasis							 China*
<b>Delgocitinib</b> LP0133	Topical pan-JAK inhibitor	Chronic hand eczema							 Global
<b>Tralokinumab**</b> LP0162	Anti-IL-13 monoclonal antibody	Atopic Dermatitis (Pediatrics)							 Global
		Atopic dermatitis (AD on hands)							 Global
<b>Temtokibart</b> LP0145	Anti-IL-22RA1 monoclonal antibody	Atopic dermatitis							 Global
<b>LEO158968</b> LP0189	Monoclonal antibody	Inflammatory skin diseases							 Global

*Project compounds in our pipeline are investigational and have not been approved in the listed indications and regions by regulatory authorities.*

*\*Approved in the EU and US for plaque psoriasis.*

*\*\*Approved in the EU and US for atopic dermatitis in adults and adolescents.*